Detalles de la búsqueda
1.
Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer: a retrospective analysis of 1601 cases at a single cancer center.
Chin J Cancer
; 34(10): 475-82, 2015 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-26411553
2.
A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
Cancer
; 120(9): 1379-86, 2014 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24481719
3.
Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
Ann Surg Oncol
; 21(6): 2091-6, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24585406
4.
Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Oncotarget
; 6(13): 11704-13, 2015 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25868976
5.
Expression of Cystatin SN significantly correlates with recurrence, metastasis, and survival duration in surgically resected non-small cell lung cancer patients.
Sci Rep
; 5: 8230, 2015 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-25648368
6.
Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.
PLoS One
; 9(7): e102777, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25029199
Resultados
1 -
6
de 6
1
Próxima >
>>